LLY

1,006.06

+1.27%↑

JNJ

209.91

+1.6%↑

ABBV

223.8

-0.55%↓

UNH

336.55

+2.68%↑

AZN

90.26

-1.28%↓

LLY

1,006.06

+1.27%↑

JNJ

209.91

+1.6%↑

ABBV

223.8

-0.55%↓

UNH

336.55

+2.68%↑

AZN

90.26

-1.28%↓

LLY

1,006.06

+1.27%↑

JNJ

209.91

+1.6%↑

ABBV

223.8

-0.55%↓

UNH

336.55

+2.68%↑

AZN

90.26

-1.28%↓

LLY

1,006.06

+1.27%↑

JNJ

209.91

+1.6%↑

ABBV

223.8

-0.55%↓

UNH

336.55

+2.68%↑

AZN

90.26

-1.28%↓

LLY

1,006.06

+1.27%↑

JNJ

209.91

+1.6%↑

ABBV

223.8

-0.55%↓

UNH

336.55

+2.68%↑

AZN

90.26

-1.28%↓

Search

Ligand Pharmaceuticals Inc

Закрыт

СекторЗдравоохранение

181.99 -0.62

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

179.25

Макс.

185.95

Ключевые показатели

By Trading Economics

Доход

112M

117M

Продажи

115M

P/E

Средняя по отрасли

81.352

77.671

Рентабельность продаж

101.569

Сотрудники

68

EBITDA

87M

149M

Рекомендации

By TipRanks

Рекомендации

Активная покупка

Прогноз на 12 месяцев

+31.03% upside

Рыночная статистика

By TradingEconomics

Рыночная капитализация

-485M

3.6B

Предыдущая цена открытия

182.61

Предыдущая цена закрытия

181.99

Новостные настроения

By Acuity

56%

44%

329 / 374 Рейтинг в Healthcare

Техническая оценка

By Trading Central

Уверенность

Strong Bearish Evidence

Ligand Pharmaceuticals Inc График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

10 дек. 2025 г., 22:02 UTC

Отчет

Synopsys Sees Strong 2026 as Ansys Acquisition Boosts 4Q Revenue

10 дек. 2025 г., 21:46 UTC

Отчет

Adobe Expects Double-Digit Recurring Revenue Growth Next Year

10 дек. 2025 г., 23:52 UTC

Приобретения, слияния, поглощения

Paramount Sends Letter to Warner Bros. Shareholders Saying Its Offer Is 'Superior' -- Barrons.com

10 дек. 2025 г., 23:43 UTC

Обсуждения рынка

Nikkei May Rise After Fed Rate Cut -- Market Talk

10 дек. 2025 г., 23:36 UTC

Обсуждения рынка

Gold Consolidates as Traders Digest FOMC Decision -- Market Talk

10 дек. 2025 г., 23:20 UTC

Отчет

Oracle Reports $16.1 Billion in Revenue, Narrowly Missing Forecasts -- 2nd Update

10 дек. 2025 г., 23:15 UTC

Отчет

Synopsys Targets Double-Digit Growth Following Ansys Acquisition -- Interview

10 дек. 2025 г., 22:59 UTC

Обсуждения рынка
Отчет
Приобретения, слияния, поглощения

Adobe Expects Semrush Deal to Bring in New Users -- Market Talk

10 дек. 2025 г., 22:45 UTC

Обсуждения рынка

Coca-Cola's New CEO Pick Looks A Lot Like The Last One -- Market Talk

10 дек. 2025 г., 22:40 UTC

Отчет

Synopsys Stock Rises on Earnings Beat, Higher Guidance -- Barrons.com

10 дек. 2025 г., 22:06 UTC

Приобретения, слияния, поглощения

Paramount Sends Letter to Warner Bros. Shareholders Saying Their Offer Is 'Superior' -- Barrons.com

10 дек. 2025 г., 22:06 UTC

Отчет

Oracle Reports Mixed Earnings. The Stock Is Falling. -- Barrons.com

10 дек. 2025 г., 22:02 UTC

Отчет

Synopsys Stock Rises on Earnings Beat, Higher Guidance -- Barrons.com

10 дек. 2025 г., 22:00 UTC

Отчет

Oracle Reports $16.1 Billion in Revenue, Narrowly Missing Forecasts -- Update

10 дек. 2025 г., 21:53 UTC

Отчет

Adobe Earnings Show 'Rapid Adoption' of AI Tools. The Stock Is Up. -- Barrons.com

10 дек. 2025 г., 21:50 UTC

Приобретения, слияния, поглощения

Investors Bet That a Higher Bid for Warner Is Coming -- Update

10 дек. 2025 г., 21:50 UTC

Обсуждения рынка
Отчет
Приобретения, слияния, поглощения

Financial Services Roundup: Market Talk

10 дек. 2025 г., 21:50 UTC

Обсуждения рынка

Health Care Roundup: Market Talk

10 дек. 2025 г., 21:50 UTC

Обсуждения рынка

Auto & Transport Roundup: Market Talk

10 дек. 2025 г., 21:45 UTC

Приобретения, слияния, поглощения

Paramount Sends Letter to Warner Bros. Shareholders Saying Their Offer Is 'Superior' -- Barrons.com

10 дек. 2025 г., 21:33 UTC

Отчет

Oracle Reports $16.1 Billion in Revenue, Narrowly Missing Forecasts -- WSJ

10 дек. 2025 г., 21:32 UTC

Отчет

Oracle Reports Mixed Earnings. The Stock Is Falling. -- Barrons.com

10 дек. 2025 г., 21:28 UTC

Приобретения, слияния, поглощения

Sverica Capital Management Announces Sale of Coastal Cloud Holdings to Tata Consultancy Services for $700M

10 дек. 2025 г., 21:25 UTC

Отчет

Adobe Earnings Show 'Rapid Adoption' of AI Tools. The Stock Is Up. -- Barrons.com

10 дек. 2025 г., 21:18 UTC

Приобретения, слияния, поглощения

Paramount Skydance: Company Has Air Tight Financing to Deliver on Warner Bros. Offer >PSKY

10 дек. 2025 г., 21:16 UTC

Отчет

Oracle Reports Mixed Earnings. The Stock is Falling. -- Barrons.com

10 дек. 2025 г., 21:15 UTC

Приобретения, слияния, поглощения

Paramount Skydance: Public Offer for Warner Bros. Delivers Superior Value, Faster, More Certain Path to Completion

10 дек. 2025 г., 21:15 UTC

Отчет

Oracle: 'Sold Ampere Because We No Longer Think It Is Strategic for Us to Continue Designing, Manufacturing and Using Our Own Chips in Our Cloud Datacenters' >ORCL

10 дек. 2025 г., 21:14 UTC

Отчет

Oracle 2Q Non-GAAP Operating Income Was $6.7 B >ORCL

10 дек. 2025 г., 21:14 UTC

Отчет

Oracle 2Q GAAP Operating Income Was $4.7 B >ORCL

Сравнение c конкурентами

Изменение цены

Ligand Pharmaceuticals Inc Прогноз

Целевая цена

By TipRanks

31.03% рост

Прогноз на 12 месяцев

Средняя 243.5 USD  31.03%

Максимум 275 USD

Минимум 220 USD

Основано на мнении 7 аналитиков Wall Street, спрогнозировавших целевые цены для Ligand Pharmaceuticals Inc на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Активная покупка

7 ratings

7

Покупка

0

Удержание

0

Продажа

Техническая оценка

By Trading Central

102.5 / 109.24Поддержка и Сопротивление

Краткосрочная

Strong Bearish Evidence

Среднесрочная

Very Strong Bearish Evidence

Долгосрочная

Weak Bullish Evidence

Настроения

By Acuity

329 / 374Рейтинг в Здравоохранение

Новостные настроения

Свидетельства нисходящего тренда

Волатильность

Ниже среднего

Объем новостей (RCV)

Выше среднего

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

$

О компании Ligand Pharmaceuticals Inc

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression; and Veklury, an antiviral treatment for moderate or severe COVID-19. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in Jupiter, Florida.
help-icon Live chat